Tags Archive Navigation
icon
-
Media ReleaseNovartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
-
Media ReleaseNovartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
-
Media ReleaseNovartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
-
Media ReleaseNovartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
-
Media ReleaseNovartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
-
Media ReleaseNovartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
-
Media ReleaseNovartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
-
Media ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
-
Media ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
-
Media ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
-
Media ReleaseNovartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
-
Media ReleaseNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD